MX2020002235A - Composicion para la estimulacion ovarica controlada. - Google Patents

Composicion para la estimulacion ovarica controlada.

Info

Publication number
MX2020002235A
MX2020002235A MX2020002235A MX2020002235A MX2020002235A MX 2020002235 A MX2020002235 A MX 2020002235A MX 2020002235 A MX2020002235 A MX 2020002235A MX 2020002235 A MX2020002235 A MX 2020002235A MX 2020002235 A MX2020002235 A MX 2020002235A
Authority
MX
Mexico
Prior art keywords
composition
ovarian stimulation
controlled ovarian
controlled
fsh
Prior art date
Application number
MX2020002235A
Other languages
English (en)
Inventor
Lisbeth Helmgaard
Bjarke Mirner Klein
Saez Joan - Carles Arce
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2020002235A publication Critical patent/MX2020002235A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Preparaciones que incluyen FSH, por ejemplo, FSH recombinante, para el uso en el tratamiento de la infertilidad en pacientes que tienen AMH alta y peso corporal bajo.
MX2020002235A 2017-09-01 2018-08-31 Composicion para la estimulacion ovarica controlada. MX2020002235A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
PCT/EP2018/073442 WO2019043143A1 (en) 2017-09-01 2018-08-31 COMPOSITION FOR CONTROLLED OVARIAN STIMULATION

Publications (1)

Publication Number Publication Date
MX2020002235A true MX2020002235A (es) 2020-07-20

Family

ID=59772482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002235A MX2020002235A (es) 2017-09-01 2018-08-31 Composicion para la estimulacion ovarica controlada.

Country Status (30)

Country Link
US (2) US11744879B2 (es)
EP (2) EP3973982A1 (es)
JP (2) JP6856819B2 (es)
KR (1) KR20200045543A (es)
CN (1) CN111050787A (es)
AR (1) AR112541A1 (es)
AU (1) AU2018326556A1 (es)
BR (1) BR112020003379A2 (es)
CA (1) CA3073624A1 (es)
CL (1) CL2020000482A1 (es)
DK (1) DK3675894T3 (es)
EA (1) EA202090480A1 (es)
ES (1) ES2904787T3 (es)
HR (1) HRP20211802T1 (es)
HU (1) HUE056726T2 (es)
IL (1) IL272763B2 (es)
JO (1) JOP20200034A1 (es)
LT (1) LT3675894T (es)
MA (2) MA50034B1 (es)
MD (1) MD3675894T2 (es)
MX (1) MX2020002235A (es)
PH (1) PH12020500404A1 (es)
PL (1) PL3675894T3 (es)
PT (1) PT3675894T (es)
RS (1) RS62810B1 (es)
SG (1) SG11202003840QA (es)
SI (1) SI3675894T1 (es)
TW (1) TWI749255B (es)
UA (1) UA126869C2 (es)
WO (1) WO2019043143A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2397680A1 (en) * 2000-01-27 2001-08-02 Applied Research Systems Ars Holding N.V. Use of fsh for treating infertility
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2009036771A1 (es) * 2007-09-21 2009-03-26 Pharmabrand S.A. Composición de polisacáridos mucilaginosos, derivados de aloe barbadensis, en combinación con liposomas, procedimiento de obtención y uso de la misma como fotoprotectora, antiacné, regeneradora de la epidermis e hidratante
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
US20130045933A1 (en) * 2010-01-21 2013-02-21 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
FI2621517T4 (fi) 2010-09-29 2024-01-03 Ferring Bv Koostumus käytettäväksi hedelmättömyyden hoidossa
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
CN106413735A (zh) * 2014-04-18 2017-02-15 葛莱高托普有限公司 利用改进的重组人卵泡刺激素的控制性超促排卵
RS65096B1 (sr) 2015-02-26 2024-02-29 Ferring Bv Menotropin za lečenje neplodnosti
PL3283097T3 (pl) 2015-04-17 2020-10-19 Ferring B.V. FSH do leczenia niepłodności
CN114107315A (zh) 2015-04-24 2022-03-01 辉凌公司 产生促性腺激素的方法
ES2770860T3 (es) 2015-06-26 2020-07-03 Ferring Bv Métodos de purificación y/o inactivación viral
JP2021522268A (ja) 2018-04-30 2021-08-30 フェリング ベスローテン フェンノートシャップ 制御された卵巣刺激のための組成物
EP3866833A1 (en) 2018-10-17 2021-08-25 Ferring BV Compositions and methods for controlled ovarian stimulation

Also Published As

Publication number Publication date
JP7373479B2 (ja) 2023-11-02
TWI749255B (zh) 2021-12-11
JP2021046398A (ja) 2021-03-25
DK3675894T3 (da) 2022-01-24
SI3675894T1 (sl) 2022-01-31
KR20200045543A (ko) 2020-05-04
MA50034A (fr) 2021-05-12
EP3675894A1 (en) 2020-07-08
TW201919687A (zh) 2019-06-01
SG11202003840QA (en) 2020-05-28
MA56224A (fr) 2022-04-20
AR112541A1 (es) 2019-11-06
MD3675894T2 (ro) 2022-03-31
RS62810B1 (sr) 2022-02-28
CL2020000482A1 (es) 2020-06-26
ES2904787T3 (es) 2022-04-06
JOP20200034A1 (ar) 2020-02-13
US11744879B2 (en) 2023-09-05
EP3973982A1 (en) 2022-03-30
PH12020500404A1 (en) 2021-03-01
AU2018326556A1 (en) 2020-03-05
IL272763B2 (en) 2024-02-01
US20240024424A1 (en) 2024-01-25
HRP20211802T1 (hr) 2022-03-04
JP6856819B2 (ja) 2021-04-14
CN111050787A (zh) 2020-04-21
JP2020528071A (ja) 2020-09-17
CA3073624A1 (en) 2019-03-07
HUE056726T2 (hu) 2022-03-28
US20200197493A1 (en) 2020-06-25
UA126869C2 (uk) 2023-02-15
PT3675894T (pt) 2022-01-25
MA50034B1 (fr) 2022-02-28
IL272763A (en) 2020-04-30
EP3675894B1 (en) 2021-11-03
WO2019043143A1 (en) 2019-03-07
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
EA202090480A1 (ru) 2020-07-20
IL272763B1 (en) 2023-10-01
BR112020003379A2 (pt) 2020-08-25

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
JO3092B1 (ar) مركب لتحفيز مسيطر عليه للمبيض
EP4218809A3 (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
PH12017501300A1 (en) Novel iodophor composition and methods of use
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2020003762A (es) Composiciones cosmeticas y metodo para tratar la piel.
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2018002921A (es) Composicion de hormona foliculo-estimulante mamifera con estabilidad incrementada.
NZ762312A (en) Anti-pacap antibody
PH12020500079A1 (en) Novel substituted xanthine derivates
MX2021006102A (es) Suministro mejorado de agentes grandes.
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
PH12020500404A1 (en) Composition for controlled ovarian stimulation
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2017013879A (es) Composiciones que comprenden anakinra.
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.